Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma
Status:
Recruiting
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
This is a Pilot/Phase I clinical study of hyperpolarized 13C (HP 13C) pyruvate injection that
includes the acquisition of magnetic resonance (MR) data performed on participants with
meningioma to evaluate metabolism and aid in the non-invasive characterization of aggressive
tumor behavior
Phase:
Phase 1
Details
Lead Sponsor:
Javier Villaneuva-Meyer, MD
Collaborators:
General Electric National Institute for Biomedical Imaging and Bioengineering (NIBIB)